India’s pharmaceutical export sector has recorded an impressive 18% growth in the first quarter of fiscal year 2026-27 (April–June 2026), driven by a surge in US ANDA (Abbreviated New Drug Application) approvals and robust demand from African markets, according to industry data released by Pharmexcil and leading financial analysts.
Quarterly Performance Highlights
The Q1 FY27 performance builds on the strong momentum from FY26, where Indian pharmaceutical exports crossed the USD 30 billion mark for the first time. Key players such as Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla have led the charge, with each reporting double-digit export revenue growth.
- Sun Pharma: Reported a 22% increase in US formulation sales, driven by its specialty pipeline and generic launches.
- Dr. Reddy’s: Recorded a 16% rise in global generics revenue, fueled by new product launches in the US and emerging markets.
- Cipla: Achieved a 19% growth in its API and formulation exports, particularly to African and Southeast Asian markets.
USFDA ANDA Approvals: A Key Growth Driver
The US market remains the largest destination for Indian generic pharmaceutical exports. In April and May 2026, the USFDA granted a total of 47 final ANDA approvals to Indian manufacturers, reflecting the continued confidence of the global regulator in India’s pharmaceutical manufacturing capabilities.
This approval rate represents a 12% increase compared to the same period in the previous fiscal year, signaling a robust pipeline of generic drug launches in the US market for the remainder of 2026.
Africa Market Expansion
African markets have emerged as the second-largest growth driver, with exports to the continent rising by 24% year-over-year in Q1. This growth is attributed to increased healthcare spending, WHO prequalification of several Indian generics for HIV/AIDS, malaria, and tuberculosis, and the expansion of local partnership agreements.
India’s role as the “pharmacy of the developing world” has been further strengthened by recent WHO prequalification of eight Indian generic drugs in May 2026, including tenofovir/lamivudine/dolutegravir for HIV (by Mylan/Viatris) and artesunate for malaria (by Ipca Laboratories).
PLI Scheme Supporting Export Growth
The Indian government’s Production Linked Incentive (PLI) scheme for pharmaceuticals continues to support the export ecosystem. As of May 2026, the scheme has achieved 90% of its disbursement target for FY26, with over 50 new API (Active Pharmaceutical Ingredient) and KSM (Key Starting Material) manufacturing units now operational. This reduces India’s dependence on Chinese API imports and strengthens the overall supply chain for Indian generic drug exports.
Outlook for FY27
Industry analysts project that India’s pharmaceutical exports could reach USD 35-36 billion for the full fiscal year 2026-27, buoyed by continued ANDA approvals, expanding biosimilar portfolios, and growing demand from emerging markets. The US generic drug market alone is expected to see 8-10 new first-to-file launches by Indian companies in 2026.
For buyers seeking verified Indian generic pharmaceutical suppliers, the IMSDA member directory provides a comprehensive list of vetted and reliable distributors and manufacturers.
Disclaimer: This article is for informational purposes only and does not constitute investment or medical advice. Export data and projections are based on publicly available industry reports and analyst estimates as of May 2026.